Eyenovia

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eyenovia anticipates FDA approval for MydCombi, focusing on growth

Eyenovia's Q4 2022 call highlighted financial results, key milestones, and upcoming FDA approval for MydCombi. The company's focus on product candidates and strategic partnerships positions it for growth.

Eyenovia reports FDA approval for MydCombi, eyes ophthalmology market growth

Eyenovia's Q1 2023 performance reflects financial discipline and strategic progress in product development and partnerships, positioning the company for future growth.
The company's focus on efficiency, market potential in ophthalmology, and innovative products like Optejet present opportunities for expansion and value creation.
Challenges lie in raising awareness about new products, balancing financial discipline with growth ambitions, and successfully executing product launches in competitive markets.

Eyenovia reports Q2 loss but hits milestones, eyes growth opportunities

Eyenovia's Q2 2023 performance reflects a net loss but highlights successful commercial milestones for Mydcombi and progress on Apersure.
The company's strengths lie in innovation with Optejet technology, expanding manufacturing capabilities, and promising licensing agreements.
Challenges include managing losses, finalizing partnerships, and meeting regulatory timelines, while opportunities exist in partnerships, market expansion, and revenue growth.
Overall, Eyenovia's strategic focus on product development, partnerships, and financial management positions it for future growth and success in the pharmaceutical industry.

Eyenovia reports Q3 losses, eyes FDA approvals and strategic partnerships

Eyenovia's Q3 performance reflects strategic investments in product development and partnerships to drive future growth. The company's focus on innovative products like Mydcombi and APP13007 positions them well for market expansion. While facing financial challenges and regulatory risks, Eyenovia's strong leadership and partnership progress indicate a promising outlook for the future.

Eyenovia reports Q4 progress with FDA approvals and revenue strategies

Eyenovia's Q4 2023 earnings call highlighted progress in product development, manufacturing capabilities, and revenue potential.
The company's focus on innovation, competitive pricing, and strategic partnerships positions it for future growth and market success.
Challenges include market competition, operational expenses, and the need for promotional efforts to drive product adoption.
Opportunities lie in collaborations, product launches, and strategic initiatives to enhance market presence and drive revenue growth.

Eyenovia reports Q1 loss but eyes revenue growth opportunities

Eyenovia's Q1 2024 performance reflects a focus on commercialization, pipeline advancement, and strategic collaborations amidst a net loss and increased expenses.
With a strong product portfolio, differentiated offerings, and key partnerships, Eyenovia is well-positioned to capitalize on revenue opportunities in the eye care market.
While facing challenges in managing costs and securing capital, Eyenovia has opportunities to drive growth through product launches, market expansion, and regulatory milestones.

Eyenovia reports Q2 loss but sees growth potential in innovations

Eyenovia's Q2 2024 performance reflects strategic investments in product development and partnerships, with a focus on innovative technologies like Optejet.
While facing financial challenges from increased expenses, Eyenovia's revenue potential from licensing agreements and product pipeline remains strong.
The company's opportunities lie in capitalizing on Optejet advancements, expanding market reach through collaborations, and navigating regulatory milestones for key products.

Eyenovia advances in pediatric eye care amidst financial challenges

Eyenovia's Q3 2024 performance reflects progress in innovation and market expansion, despite financial losses.
The company's strengths lie in pediatric eye care, self-administration technology, and strategic collaborations driving revenue potential.
Challenges include financial losses, cost management, and competitive pressures, while opportunities exist in product validation, market expansion, and revenue growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

On track with VISION-2 phase 3 presbyopia trial and expedited resubmission of MydCombi™ New Drug Application as a drug/device combination in early 2022

Eyenovia Reports Third Quarter 2021 Financial Results

Eyenovia is an under-the-radar ophthalmic company with a large addressable market and big opportunities ahead just received a Complete Response Letter (CRL) from the FDA for its leading drug candidate.

Eyenovia: FDA Setback Is Big Opportunity For Investors

Discussion to Include Future Potential Treatment Options, Including MicroPine (atropine ophthalmic spray), for reduction of myopia progression in pediatrics Discussion to Include Future Potential Treatment Options, Including MicroPine (atropine ophthalmic spray), for reduction of myopia progression in pediatrics

Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting

Eyenovia will release third quarter 2021 results on Wednesday, November 10, after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be released on Thursday, November 11, after the close.

CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10

Company to host an investor conference call and webcast at 5:00pm ET on that day Company to host an investor conference call and webcast at 5:00pm ET on that day

Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11

Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022

Eyenovia Announces First Patient Enrolled in Phase 3 VISION-2 Trial of MicroLine for Presbyopia

NEW YORK, Nov. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eyenovia, Inc. ("Eyenovia" or the "Company") (NASDAQ: EYEN).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Eyenovia, Inc. - EYEN

Genus Medical Technologies, LLC v. FDA legal case leads to agency-wide review and reclassification of eye cups, eye droppers, and ophthalmic dispensers

Eyenovia Announces Reclassification of MydCombi(tm) as Drug-Device Combination Product by FDA

A late-stage biotech company with three products in their pipeline.

Eyenovia: Can You See Me Now?

Eyenovia (EYEN) has been struggling lately, but the selling pressure may be coming to an end soon.

Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy?

Alto Ingredients

Cocrystal Pharma

Hall of Fame Resort & Entertainment

Scopus BioPharma

5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Best Penny Stocks To Buy Right Now According To Insiders

Eyenovia's (EYEN) Management on Q2 2021 Results - Earnings Call Transcript

Announced positive topline data from its Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia

Eyenovia Reports Second Quarter 2021 Financial Results

NEW YORK & LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- #ASCRS2021--Eyenovia will participate in a July 22 Eyecelerator@ASCRS panel, entitled, “Presbyopia: Everybody gets it... but can it be fixed?” 

Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that management will present a corporate overview and host one-one-one meetings at the Ladenburg Thalmann 2021 Healthcare Conference, being held virtually July 13-14, 2021, and host one-on-meetings at the William Blair Biotech Focus Conference 2021, being held virtually July 14-15, 2021.

Eyenovia to Participate in Two Upcoming Investor Conferences

Eyenovia is a specialty ophthalmic company that I have previously recommended. The company has three drugs in its pipeline - MydCombi, MicroLine, and MicroPine - all using Eyenovia's proprietary Optejet microdose dispenser.

Eyenovia: Recent MicroLine Data, October MydCombi PDUFA Date Bode Well For Value Creation

Eyenovia Inc (NASDAQ: EYEN) has announced topline data from its VISION-1 Phase 3 study evaluating MicroLine, for the temporary improvement of near vision in adults with presbyopia. The results will be presented at a future ophthalmic-focused medical meeting.

Eyenovia Stock Shoots Higher on Positive MicroLine Data in Late-Stage Presbyopia Study

Primary endpoint was achieved with well-tolerated micro-array print (MAP™) safety profile

Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia

Eyenovia is developing new products and solutions in the ophthalmology markets which are set to increase efficiency and lower costs for those with various eye disorders and conditions.

Eyenovia: Still A Great Long-Term Investment In Ophthalmology

Eyenovia's (EYEN) CEO Sean Ianchulev on Q1 2021 Results - Earnings Call Transcript

MydCombi PDUFA date confirmed for October 28, 2021

Eyenovia Reports First Quarter 2021 Financial Results

NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the company has entered into a new $25 million credit financing facility with Silicon Valley Bank (SVB).

Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank

Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day

Eyenovia to Report First Quarter 2021 Results on Wednesday, May 12

NEW YORK--(BUSINESS WIRE)-- #EYEN--Dr. Julia Haller brings experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader to her role as an Eyenovia director.

Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors

Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2020 Results - Earnings Call Transcript

News for Eyenovia Stock (EYEN)